To determine the effect of IL-19 in progression of pulmonary fibrosis in vivo, we, respectively, administered a single dose of IL-19 (200 ng/kg) or BLM (2.5 mg/kg) or combination of these two treatments to wild-type C57BL/6 mice by intratracheal route. The gene discussed is IL19; the disease is pulmonary fibrosis.